Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.

被引：2
|
作者：
Bhatia, Aarti K.
Mehra, Ranee
Khan, Saad A.
Egleston, Brian L.
Alpaugh, R. Katherine
Lango, Miriam
Ridge, John A.
Burtness, Barbara
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6027
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Bourhis, Jean
    Rivera, Fernando
    Mesia, Ricard
    Awada, Ahmad
    Geoffrois, Lionel
    Borel, Christian
    Humblet, Yves
    Lopez-Pousa, Antonio
    Hitt, Ricardo
    Vega Villegas, M. Eugenia
    Duck, Lionel
    Rosine, Dominique
    Amellal, Nadia
    Schueler, Armin
    Harstrick, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2866 - 2872
  • [22] Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
    Tahara, M.
    Kiyota, N.
    Yokota, T.
    Hasegawa, Y.
    Muro, K.
    Takahashi, S.
    Onoe, T.
    Homma, A.
    Taguchi, J.
    Suzuki, M.
    Minato, K.
    Yane, K.
    Ueda, S.
    Hara, H.
    Saijo, K.
    Yamanaka, T.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 1004 - 1009
  • [23] Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: A phase II study
    Fountzilas, G
    Athanassiadis, A
    Samantas, E
    Skarlos, D
    KalogeraFountzila, A
    Nikolaou, A
    Bacoyiannis, H
    Stathopoulos, G
    Kosmidis, P
    Daniilidis, J
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S65 - S67
  • [24] Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first- line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara, Makoto
    Kiyota, Naomi
    Yokota, Tomoya
    Hasegawa, Yasuhisa
    Muro, Kei
    Takahashi, Shunji
    Onoe, Takuma
    Homma, Akihiro
    Taguchi, Jun
    Suzuki, Masami
    Minato, Koichi
    Yane, Katsunari
    Ueda, Shinya
    Hara, Hiroki
    Saijo, Ken
    Yamanaka, Takeharu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] WEEKLY REGIMEN OF PACLITAXEL-CARBOPLATIN-CETUXIMAB IN PATIENTS WITH RECURRENT SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SCCNH): RESULTS OF A MONOCENTRIC EXPERIENCE
    Rozzi, A.
    Corona, M.
    Nardoni, C.
    Restuccia, M. R.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 44 - 44
  • [26] Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma
    Sheth, Siddharth
    Gilbert, Jill
    Deal, Allison Mary
    Chera, Bhishamjit
    Murphy, Barbara
    Woods, Justin
    Miller, Kelsey
    Weissler, Mark
    Hackman, Trevor
    Liao, Jay Justin
    Olson, Juneko Grilley
    Hayes, David Neil
    Weiss, Jared
    ORAL ONCOLOGY, 2022, 127
  • [27] Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
    Chevalier, Thomas
    Daste, Amaury
    Saada-Bouzid, Esmaa
    Loundou, Anderson
    Peyraud, Florent
    Lambert, Tiphaine
    Le Tourneau, Christophe
    Peyrade, Frederic
    Dupuis, Charlotte
    Alfonsi, Marc
    Fayette, Jerome
    Reure, Juliette
    Huguet, Florence
    Fakhry, Nicolas
    Toullec, Clemence
    Salas, Sebastien
    CANCER MEDICINE, 2021, 10 (12): : 3952 - 3963
  • [28] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [29] Cetuximab, Paclitaxel, Carboplatin, and Radiation For Head and Neck Cancer A Toxicity Analysis
    Birnbaum, Ariel
    Dipetrillo, Thomas
    Rathore, Ritesh
    Anderson, Elliott
    Wanebo, Harry
    Puthwala, Yacoub
    Joyce, Donald
    Safran, Howard
    Henderson, Denise
    Kennedy, Theresa
    Ready, Neal
    Sio, Terence Tai-Weng
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 144 - 147
  • [30] A comparison of cetuximab-containing regimens for recurrent/metastatic squamous cell head and neck carcinoma: the clinical significance of weekly paclitaxel and cetuximab
    Nakano, K.
    Marshall, S.
    Taira, S.
    Sato, Y.
    Tomomatsu, J.
    Sasaki, T.
    Shimbashi, W.
    Fukushima, H.
    Yonekawa, H.
    Mitani, H.
    Kawabata, K.
    Takahashi, S.
    ANNALS OF ONCOLOGY, 2016, 27
12345